A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

New ER-REBOA™ PLUS Aortic Occlusion Catheter is Launched

Prytime Medical Devices, Inc. introduced its latest aortic occlusion catheter, the ER-REBOA™ PLUS this week at the American Association for the Surgery of Trauma (AAST) Annual Meeting.

Prytime Medical Devices notes it is designed for improved ease of use, it is REBOA refined for controlling massive non-compressible hemorrhage.

“The original ER-REBOA™ catheter was an important start in delivering a new technology to help clinicians stabilize and manage certain scenarios of bleeding and shock; a technology that, to date, has contributed to saving hundreds of lives,” said Col. (Dr.) Todd Rasmussen, Director of the Battlefield Shock and Resuscitation Research Program at the Uniformed Services University of the Health Sciences. “However, we recognized from the outset that the original design and device would evolve. Even iterative changes in the technology, such as with the ER-REBOA™ PLUS, stand to make the devices easier to use, safer and more effective.”

“ER-REBOA™ PLUS represents the evolution of REBOA based on experience and input from civilian trauma surgeons,” said David Spencer, CEO, Prytime. “The civilian marketplace believes that no one should bleed to death, and the sooner you stop the bleeding the better. The ER-REBOA™ PLUS catheter was developed to help doctors preserve their clinical options for optimal care and best outcomes.”

 

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy